Unmet Needs in Oligometastatic Prostate Cancer
Chad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.
Chad Tang, MD, The University of Texas MD Anderson Cancer Center, discusses the unmet needs for patients with oligometastatic prostate cancer.
There have been randomized trials for oligometastatic prostate cancer, including STOMP (NCT01558427) and ORIOLE (NCT02680587), which randomized patients to receive radiation in metastatic patients vs observation. These trials showed that radiation delayed the PSA progression that occurs among this patient population, and radiation by itself, delays the progression.
According to Tang, other trials have also shown that radiation therapy can combine synergistically with hormone therapy. In earlier trials, upfront hormonal therapy for metastatic disease has also resulted in benefits in overall survival when compared with delaying hormone therapy.
Then, the EXTEND trial (NCT03599765) recently evaluated patients with oligometastatic prostate cancer and showed there to be improvements in progression-free survival (PFS) and eugonadal PFS when given the combination of metastasis-directed therapy with intermittent hormone therapy.
However, Tang notes that questions still remain regarding how experts think about oligometastatic prostate cancer, the way it is defined, and how it is treated.
Transcription:
0:10 | I think the biggest unmet need is how we think about oligometastatic prostate cancer. In my opinion, there are 2 ways that you can change therapy with high level evidence. One is to do a randomized control compared with standard of care and number 2 is staging changes. With PSMA PETS and with improved imaging overall, maybe we need to better define, biologically, what oligometastatic prostate cancer is. If that's true, then maybe we should treat them like metastatic prostate cancers to understand these processes a little bit better and find the optimum treatment recommendations for these patients.
REFERENCE:
Tang C, Sherry AD, Haymaker C, et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer (EXTEND): A multicenter, randomized phase II trial. J Radiat Oncol. 2022;114(5):P1059-1060. doi:10.1016/j.ijrobp.2022.09.006
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
